Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An article written by Fox Business referenced a June 2019 contributor piece published on the website of The American Journal of Managed Care® (AJMC®). The contributor article, titled “The Deadly Costs of Insulin,” details the significant price increases of insulin treatment, which has seen insulin lispro, sold as Humalog, rise in cost by 1200% since 1996.
A study published in the December 2019 issue of AJMC®, “Cost-Sharing Payments for Out-of-Network Care in Commercially Insured Adults,” was highlighted in both the pulmonology and cardiology briefings of Physician’s Weekly for December 2019. The study analyzed claims among adults covered by employer-sponsored plans and found substantial variations in out-of-network cost-sharing payments.
A piece by US News & World Report highlighted another study from the December 2019 issue, “Benzodiazepine and Unhealthy Alcohol Use Among Adult Outpatients.” The study found that among outpatients who were screened for alcohol use, those with unhealthy alcohol use, women, and those who were older, white, and of lower socioeconomic status were more likely to use benzodiazepines, which include drugs such as diazepam (Valium), alprazolam (Xanax), and clonazepam (Klonopin).
Fox 5 DC’s article, “FDA approves new migraine drug,” cited a June 2018 study summary published in the Migraine compendium of AJMC®, “Study Summary: Costs Associated With Migraine in the United States.” The study was additionally spotlighted by Yahoo Finance and Healthcare Business News.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen